Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F11%3A00052560" target="_blank" >RIV/00216224:14110/11:00052560 - isvavai.cz</a>

Alternative codes found

RIV/65269705:_____/11:#0001362

Result on the web

<a href="http://dx.doi.org/10.1038/leu.2011.3" target="_blank" >http://dx.doi.org/10.1038/leu.2011.3</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/leu.2011.3" target="_blank" >10.1038/leu.2011.3</a>

Result language

angličtina

Original language name

Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement

Original language description

An expert panel convened to reach a consensus regarding the optimal use of lenalidomide in combination with dexamethasone (Len/Dex) in patients with relapsed or refractory multiple myeloma (RRMM). On the basis of the available evidence, the panel agreedthat Len/Dex is a valid and effective treatment option for most patients with RRMM. As with other therapies, using Len/Dex at first relapse is more effective regarding response rate and durability than using it after multiple salvage therapies. Len/Dex may be beneficial regardless of patient age, disease stage and renal function, although the starting dose of lenalidomide should be adjusted for renal impairment and cytopenias. Long-term treatment until there is evidence of disease progression may be recommended at the best-tolerated doses of both lenalidomide and dexamethasone.

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2011

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Leukemia

ISSN

0887-6924

e-ISSN

—

Volume of the periodical

25

Issue of the periodical within the volume

5

Country of publishing house

GB - UNITED KINGDOM

Number of pages

12

Pages from-to

749-760

UT code for WoS article

000290471100002

EID of the result in the Scopus database

—